U.S. Healthtech Stock News

If you are wondering whether Hartford Insurance Group at around US$134.45 is offering fair value or a margin of safety, you are in the right place. The stock has been choppy in the short term, with a 3.9% decline over the last 7 days, a modest 1.6% return over 30 days, and a 1.9% year to date decline, while the 1 year return sits at 15.1% and the 3 year and 5 year returns are 100.5% and 125.5% respectively. These moves have kept Hartford on the radar for investors watching insurers,...

Wondering if Stride at around US$98.12 still offers value or if the best days are already priced in? This article breaks down what the numbers are really saying about the stock. The share price has been volatile, with a 0.3% slip over the last 7 days, a 14.6% gain over 30 days, a 51.9% return year to date, a 30.4% decline over the past year, and a 128.4% return over 3 years, alongside a 242.7% return over 5 years. Recent coverage has focused on how Stride fits into investor watchlists and...

We'd be surprised if Dave & Buster's Entertainment, Inc. ( NASDAQ:PLAY ) shareholders haven't noticed that the Chief...

Wondering whether Driven Brands Holdings at around US$12.66 is starting to look like value, or if the price still does not quite stack up for you. The stock has been under pressure, with returns of 4.2% over the last week, 0.5% over the past month, a 12.7% decline year to date, and a 22.5% decline over the last year. The 3 year and 5 year returns sit at 58.8% and 55.6% declines respectively. Recent coverage has focused on how the share price performance ties into the broader consumer...

Wondering if Acushnet Holdings at around US$98 per share still offers value, or if most of the opportunity is already reflected in the price. The stock has seen mixed shorter term returns, with a 1.9% decline over the last week, 6.4% over the last month, 19.5% year to date, and 59.9% over the last year. Recent attention on Acushnet Holdings has centered on its position in golf equipment and apparel and how demand trends in the sport relate to its current share price. Investors are weighing...

Wondering whether Peabody Energy at around US$26.60 is still attractive or if most of the easy gains are already behind it? This article focuses squarely on what the current price might be implying about value. The stock has returned 3.7% over the last 7 days, while the 30 day return sits at a 32.7% decline, against a backdrop of a 114.4% return over the past year and a 15.4% return over 3 years. Recent coverage has focused on Peabody Energy's position within the wider energy sector,...

Ecolab (NYSE:ECL) plans to acquire CoolIT Systems, expanding into specialized cooling solutions. The deal is supported by a US$4.8 billion financing initiative. This move broadens Ecolab's technology footprint beyond its traditional water, hygiene and infection prevention focus. Ecolab is known for its water treatment, hygiene and infection prevention solutions across industrial, institutional and healthcare customers. Adding CoolIT Systems brings exposure to advanced cooling technology, an...

Coastal Carolina Bancshares (CCNB) has opened 2026 with Q1 revenue of about US$9.8 million and basic EPS of US$0.43, alongside trailing twelve month revenue of roughly US$40.7 million and EPS of US$1.56 that reflect earnings growth of 27.1% over the past year. Over recent quarters, revenue has moved from US$9.3 million in Q1 2025 to US$10.4 million in Q4 2025 and EPS has ranged from US$0.39 to US$0.48. This gives investors a clear set of reference points for assessing the latest print. With a...

Prosperity Bancshares has secured all required regulatory approvals for its acquisition of Stellar Bancorp. The shareholder vote on the transaction is scheduled, with the deal expected to close in the coming months. The combination is set to expand Prosperity Bancshares' footprint in the Texas banking market. For investors tracking Prosperity Bancshares (NYSE:PB), the cleared regulatory path comes with the stock recently trading at $68.66. Over the past 3 years the shares have returned...

Wondering whether StandardAero at a last close of US$24.54 is a bargain or a value trap? This article walks through what the current price might be implying. The stock has seen an 8.3% decline over the last 7 days, a 3.6% decline over the last 30 days, and is down 17.2% year to date, with a 7.3% decline over the last year. These moves can change how the market is pricing risk and return. Recent coverage has focused on StandardAero as part of broader aerospace and defense sector discussions,...

In the past week, Travelzoo reported Q1 2026 results showing sales of US$24.27 million versus US$23.14 million a year earlier, while net income eased to US$2.48 million from US$3.17 million, with basic earnings per share from continuing operations at US$0.23. Away from the headline numbers, Travelzoo is also pushing fresh, curated Club Offers in the UK, from luxury Crete stays with private pools to experience-focused trips in the Peak District and Normandy, highlighting its emphasis on...

AppFolio (NasdaqGM:APPF) released its 2026 Renter Preferences Report focused on resident experience and leasing behavior. The report examines how satisfaction ties to lease renewals, retention, and resident advocacy across managed properties. Findings highlight the role of technology in shaping renter expectations and day to day property interactions. AppFolio, a software provider for property managers, is using this latest research to shine a light on renter behavior at a time when user...

Bgin Blockchain (BGIN) FY 2025 earnings snapshot Bgin Blockchain (BGIN) opened FY 2025 with first half revenue of about US$47.7 million and a basic EPS loss of US$0.56, setting a cautious tone for the latest results. The company has seen revenue move from US$144.5 million and EPS of US$0.85 in the first half of FY 2024 to US$157.8 million and EPS of US$0.02 in the second half. Trailing twelve month figures show revenue of roughly US$205.5 million against a net loss of US$176.9 million and EPS...

MetroCity Bankshares (MCBS) opened 2026 with Q1 revenue of US$51.7 million and basic EPS of US$0.78, with trailing twelve month revenue at US$171.7 million and EPS at US$2.81, framing the latest print against a fuller earnings picture. Over the past year, revenue has moved from US$140.7 million to US$171.7 million and EPS has shifted from US$2.55 to US$2.81, while the trailing net profit margin sits at 43.4% versus 46% a year earlier, leaving investors weighing solid profitability against...

Wondering if iRhythm Holdings at around US$122 a share still lines up with its fundamentals, or if the market is mispricing it? This article walks through what the data says about value. The stock has had a mixed run, with a 2.4% decline over the last week, a 3.6% gain over the last month, a 30.2% fall year to date, and a 15.4% return over the past year. Recent coverage has focused on how investors are reassessing high growth healthcare technology names, with sentiment shifting quickly...

If you are wondering whether Four Corners Property Trust is attractively priced at around US$25.43, the next step is to look past the headline share price and focus on what the underlying numbers suggest about value. The stock has been relatively calm over the last week with a 0.9% decline. However, the 7.3% return over 30 days and 9.4% return year to date, set against a 2.7% decline over the last year, gives mixed signals about how the market is currently viewing it. This article was...

WaterBridge Infrastructure (NYSE:WBI) has appointed Valerie Chase as an independent director. Chase will also serve as Chair of the Audit Committee, bringing extensive public company finance experience. The appointment adds further expertise to board oversight and financial reporting processes. For investors watching NYSE:WBI, this board change comes as the stock trades at $28.47, with a return of 44.4% year to date and 13.2% over the past week. Those figures may put governance moves like...

Polibeli Group's FY 2025 Earnings Snapshot Polibeli Group (NasdaqGM:PLBL) has reported its latest figures with trailing twelve month revenue of about US$26.4 million and a loss of US$5.97 million, translating to a basic EPS of US$0.016, alongside reported revenue growth of 32.6% over the past year. The company has seen revenue move from US$22.8 million in the twelve months to the second half of 2023 to US$26.4 million in the latest trailing period, while basic EPS moved from US$0.013 to...

Rithm Property Trust (RPT) opened Q1 2026 with total revenue of US$2.9 million and basic EPS of US$0.43 loss per share, giving investors a fresh look at how the business is tracking after a volatile 2025. Over the past year, revenue has moved from US$18.3 million on a trailing basis in Q4 2025 to US$22.0 million by Q1 2026, while trailing twelve month EPS has shifted from a US$0.36 loss to a US$0.30 loss. With the share price around US$14.43, the latest release puts the spotlight squarely on...

Wealthfront (WLTH) closed FY 2026 with Q4 revenue of US$96.1 million and a basic EPS loss of US$1.30, alongside trailing 12 month revenue of US$365.0 million and a trailing basic EPS loss of US$0.74. Over the past six quarters, the company has seen quarterly revenue move from US$80.3 million in Q3 2025 to US$96.1 million in Q4 2026. Basic EPS has shifted from US$0.77 in Q3 2025 to US$0.72, US$0.86 and US$0.75 in the first three quarters of 2026 before turning to a loss of US$1.30 in Q4 2026...

Wondering if Opera's recent share price puts it in the bargain bin or the overhyped aisle? This article breaks down what the numbers say about value. At a last close of US$17.23, Opera's share price comes with recent returns of 0.6% over 7 days, 25.6% over 30 days, 21.1% year to date, 16.3% over 1 year, 67.0% over 3 years, and 105.9% over 5 years. These moves sit against a backdrop of ongoing interest in Opera as a software name, with headlines frequently focusing on its role as a browser...

Wondering whether Palvella Therapeutics at around US$123.59 still offers value, or if most of the easy gains are already behind it? This article walks through what the current price could mean for you. The stock has seen a 23.2% return year to date and a 386.8% return over the last year, alongside shorter term moves of a 2.7% return over 30 days and a 4.9% decline over the past week. Recent attention on Palvella Therapeutics has centered on how the market is reassessing smaller biotech names...

If you are wondering whether Wintrust Financial at US$147.91 still offers value or is starting to look stretched, the recent share price and fundamentals give you some clear clues to work with. The stock has held up over the last week with a 0.2% decline. The 30 day return sits at 8.0% and the 1 year return at 35.6%, with longer term returns of 128.2% over 3 years and 108.7% over 5 years. Recent coverage has focused on Wintrust Financial as part of broader discussions around US regional...

FDA extends Priority Review for Savara’s molgramostim BLA in autoimmune PAP by three months following a major amendment. Regulator cites no new safety, efficacy, or manufacturing concerns in connection with the extension. Extension reflects ongoing review activity for Savara’s lead product candidate, ticker NasdaqGS:SVRA. Savara, listed on NasdaqGS:SVRA, focuses on therapies for rare respiratory diseases, with molgramostim as its most advanced program targeting autoimmune pulmonary alveolar...